Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 andLeishmania infantum | Zendy

Laurence Lachaud | Zendy; Nathalie Bourgeois | Zendy; Marie Plourde | Zendy; Philippe Leprohon | Zendy; Patrick Bastien | Zendy; Marc Ouellette | Zendy

Open Access

Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 andLeishmania infantum

Author(s) -

Laurence Lachaud,

Nathalie Bourgeois,

Marie Plourde,

Philippe Leprohon,

Patrick Bastien,

Marc Ouellette

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/595710

Subject(s) - visceral leishmaniasis , medicine , leishmania infantum , amphotericin b , leishmaniasis , immunology , incidence (geometry) , leishmania , sida , virology , viral disease , human immunodeficiency virus (hiv) , parasite hosting , antifungal , dermatology , physics , world wide web , computer science , optics

Visceral leishmaniasis (VL) is an opportunistic infection that can occur among patients infected with human immunodeficiency virus type 1 (HIV-1) in areas where both infections are endemic. Highly active antiretroviral therapy has decreased the incidence of VL in southern Europe among HIV-1-infected patients, but VL is still observed among patients with low CD4 cell counts, and most coinfected patients receiving highly active antiretroviral therapy experienced relapse, despite initial treatment with liposomal amphotericin B.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research